Richter-Helm Biologics, a joint venture of Gedeon Richter and Helm AG, established to develop and produce high-quality biotechnology products using microorganisms, announced the signing of a new agreement with us company INOVIO on the large scale production of the experimental DNA vaccine from COVID-19 – INO-4800. Currently, in the US it is already undergoing phase I clinical studies II and phase III evaluation of its effectiveness can be held this summer.
INOVIO and Richter-Helm BioLogics collaborate with 2014. The American company has already started the production of plasmids on the capacity of their partner for their further use in the development of DNA drugs. Apply production technology developed by VGXI Inc. and has proven effective in previous projects.
Company INOVIO was formed a global coalition of scientists, partners and sponsors to expedite the development of vaccines INO-4800.